Regencell Bioscience Ownership
| RGC Stock | USD 38.80 3.70 8.71% |
Shares in Circulation | First Issued 2002-06-30 | Previous Quarter 13 M | Current Value 13 M | Avarage Shares Outstanding 125.5 M | Quarterly Volatility 158.6 M |
Regencell |
Regencell Stock Ownership Analysis
About 94.0% of the company outstanding shares are owned by corporate insiders. The company has Price/Earnings To Growth (PEG) ratio of 2.15. Regencell Bioscience recorded a loss per share of 0.33. The entity last dividend was issued on the 1st of December 2017. Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine bioscience company. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong. Regencell Bioscience operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 13 people. To find out more about Regencell Bioscience Holdings contact the company at 852 2155 0823 or learn more at https://www.regencellbioscience.com.Regencell Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Regencell Bioscience is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Regencell Bioscience Holdings backward and forwards among themselves. Regencell Bioscience's institutional investor refers to the entity that pools money to purchase Regencell Bioscience's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Ubs Group Ag | 2024-12-31 | 29.2 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 2.1 K | Blackrock Inc | 2024-12-31 | 238 | Qube Research & Technologies | 2024-09-30 | 0.0 |
Regencell Bioscience Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Regencell Bioscience insiders, such as employees or executives, is commonly permitted as long as it does not rely on Regencell Bioscience's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Regencell Bioscience insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Yemenidjian Alex over two weeks ago Acquisition by Yemenidjian Alex of 4977 shares of Regencell Bioscience at 22.1 subject to Rule 16b-3 | ||
Ownby David over two months ago Acquisition by Ownby David of 19416 shares of Regencell Bioscience subject to Rule 16b-3 | ||
Bell Thomas D Jr over three months ago Acquisition by Bell Thomas D Jr of 25000 shares of Regencell Bioscience at 14.76 subject to Rule 16b-3 | ||
Kaplan Stephen A over six months ago Acquisition by Kaplan Stephen A of 10000 shares of Regencell Bioscience at 14.87 subject to Rule 16b-3 | ||
Brandow Peter B over six months ago Disposition of 1564 shares by Brandow Peter B of Regencell Bioscience at 22.97 subject to Rule 16b-3 | ||
Amy Miles over a year ago Disposition of 33006 shares by Amy Miles of Regencell Bioscience at 21.58 subject to Rule 16b-3 | ||
Peter Brandow over a year ago Disposition of 1265 shares by Peter Brandow of Regencell Bioscience at 22.87 subject to Rule 16b-3 |
Regencell Bioscience's latest congressional trading
Congressional trading in companies like Regencell Bioscience, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Regencell Bioscience by those in governmental positions are based on the same information available to the general public.
| 2017-12-21 | Senator Michael Bennet | Acquired $500,001 - $1,000,000 | Verify | ||
| 2017-04-10 | Senator Michael Bennet | Acquired $500,001 - $1,000,000 | Verify |
Regencell Bioscience Outstanding Bonds
Regencell Bioscience issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Regencell Bioscience uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Regencell bonds can be classified according to their maturity, which is the date when Regencell Bioscience Holdings has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Regencell Bioscience Corporate Filings
| 13th of March 2025 Other Reports | ViewVerify | |
6K | 15th of January 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
| 25th of October 2024 Other Reports | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regencell Bioscience Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regencell Bioscience. If investors know Regencell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regencell Bioscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Regencell Bioscience is measured differently than its book value, which is the value of Regencell that is recorded on the company's balance sheet. Investors also form their own opinion of Regencell Bioscience's value that differs from its market value or its book value, called intrinsic value, which is Regencell Bioscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regencell Bioscience's market value can be influenced by many factors that don't directly affect Regencell Bioscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regencell Bioscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Regencell Bioscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regencell Bioscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.